Filariasis: Diagnosis and treatment

Dermatologic Therapy

Volumn 22, Issue 6, 2009, Pages 475-490

  Mendoza, Natalia ^a   Li, Alexa ^b   Gill, Amber ^c   Tyring, Stephen ^c  

^a UNIVERSIDAD EL BOSQUE   (Colombia)

^b RICE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Diagnosis; Filariasis; Treatment

Indexed keywords

ALBENDAZOLE; DIETHYLCARBAMAZINE; DOXYCYCLINE; IVERMECTIN; MOXIDECTIN; PARASITE ANTIGEN;

ABDOMINAL PAIN; ANCYLOSTOMIASIS; ANOREXIA; ANTIGEN DETECTION; ARTHRALGIA; ASCARIASIS; ASTHENIA; BANCROFTIAN FILARIASIS; BLOOD SAMPLING; BRAIN DISEASE; BRUGIAN FILARIASIS; CLINICAL FEATURE; COUGHING; CUTANEOUS LARVA MIGRANS; DIPETALONEMIASIS; DIZZINESS; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESEARCH; ECHINOCOCCOSIS; ECHOGRAPHY; ELEPHANTIASIS; ENTEROBIASIS; EOSINOPHILIA; FILARIA; FILARIASIS; GEOGRAPHIC DISTRIBUTION; HAIR LOSS; HUMAN; HYDROCELE; INFECTION CONTROL; INFECTION RATE; LOEFFLER PNEUMONIA; LOIASIS; LYMPHATIC FILARIASIS; LYMPHEDEMA; LYMPHOSCINTIGRAPHY; MANSONELLIASIS; MICROFILARIASIS; MOSQUITO; MYALGIA; MYIASIS; NAUSEA; NEMATODE; NEUROCYSTICERCOSIS; NEUROLOGIC DISEASE; NONHUMAN; ONCHOCERCIASIS; PARASITE IDENTIFICATION; PARASITE VECTOR; PEDICULOSIS; POLYMERASE CHAIN REACTION; RADIOGRAPHY; REPEATED DRUG DOSE; REVIEW; SCABIES; SINGLE DRUG DOSE; SKIN BIOPSY; SORE THROAT; STRONGYLOIDIASIS; TAENIASIS; TRICHURIASIS; VACCINATION; VECTOR CONTROL; VOMITING; WORLD HEALTH ORGANIZATION;

ANTIPARASITIC AGENTS; ELEPHANTIASIS, FILARIAL; ENDEMIC DISEASES; HUMANS; INCIDENCE; WORLD HEALTH;

EID: 70449365040     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2009.01271.x     Document Type: Review

References (79)

1. Meeting of the International Task Force for Disease Eradication, October 29, 2008. Wkly Epidemiol Rec 2009 : 84 : 89 94.
2. DI G. A history of human heminthology. Oxford, UK : Oxford University Press, 1990 : 527 640.
3. Stanford University. Lymphatic filariasis. http://www.stanford.edu/class/ humbio103/ParaSites2006/Lymphatic-filariasis/index.htm. Accessed August 2009.
4. CDC. Recommendations of the International Task Force for Disease Eradication. Morb Mortal Wkly Rep 1993 : 42 : 1 38.
5. Gyapong JO, Kumaraswami V, Biswas G, Ottesen EA. Treatment strategies underpinning the global programme to eliminate lymphatic filariasis. Expert Opin Pharmacother 2005 : 6 : 179 200.
6. Ottesen EA, Hooper PJ, Bradley M, Biswas G. The global programme to eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl Trop Dis 2008 : 2 : e317.
7. Ramaiah KD, Das PK. Mass drug administration to eliminate lymphatic filariasis in India. Trends Parasitol 2004 : 20 : 499 502.
8. Sasa M. Human filariasis. Tokyo : Tokyo Press, 1976.
9. Taylor MJ, Awadzi K, Basanez MG, et al. Onchocerciasis control: vision for the future from a Ghanian perspective. Parasites & vectors 2009 : 2 : 7.
10. Nanduri J, Kazura JW. Clinical and laboratory aspects of filariasis. Clin Microbiol Rev 1989 : 2 : 39 50.
11. Palumbo E. Filariasis: diagnosis, treatment and prevention. Acta Biomed 2008 : 79 : 106 109.
12. Sauerbrey M. The Onchocerciasis Elimination Program for the Americas (OEPA). Ann Trop Med Parasitol 2008 : 102 Suppl 1 : 25 29.
13. Boatin BA, Richards FO, Jr. Control of onchocerciasis. Adv Parasitol 2006 : 61 : 349 394.
14. Centers for Disease Control and Prevention. Filariasis. http://www.dpd.cdc.gov/dpdx/HTML/Filariasis.htm. Accessed July 2009.
15. Ryan ET, Felsenstein D, Aquino SL, Branda JA, Morgan JG. Case records of the Massachusetts General Hospital. Case 39-2005. A 63-year-old woman with a positive serologic test for syphilis and persistent eosinophilia. N Engl J Med 2005 : 353 : 2697 2705.
16. Kalungi STL. Neomatoldal helminths In : Tyring SLO, Hengge U, eds, Tropical dermatology, 1st ed. Philadelphia : Elsevier Churchill Livinstone : 2006 : 57 69.
17. Burri H, Loutan L, Kumaraswami V, Vijayasekaran V. Skin changes in chronic lymphatic filariasis. Trans R Soc Trop Med Hyg 1996 : 90 : 671 674.
18. Shenoy RK. Clinical and pathological aspects of filarial lymphedema and its management. Korean J Parasitol 2008 : 46 : 119 125.
19. Yuvaraj J, Pani SP, Vanamail P, Ramaiah KD, Das PK. Impact of seven rounds of mass administration of diethylcarbamazine and ivermectin on prevalence of chronic lymphatic filariasis in south India. Trop Med Int Health 2008 : 13 : 737 742.
20. Addiss DG, Brady MA. Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature. Filaria J 2007 : 6 : 2.
21. Shenoy RK, Kumaraswami V, Suma TK, Rajan K, Radhakuttyamma G. A double-blind, placebo-controlled study of the efficacy of oral penicillin, diethylcarbamazine or local treatment of the affected limb in preventing acute adenolymphangitis in lymphoedema caused by brugian filariasis. Ann Trop Med Parasitol 1999 : 93 : 367 377.
22. Stanford University. Lymphatic filariasis. http://www.stanford.edu/class/ humbio103/ParaSites2006/Lymphatic-filariasis. Accessed May 27, 2009.
23. Hagan M. Onchocercal dermatitis: clinical impact. Ann Trop Med Parasitol 1998 : 92 Suppl 1 : S85 96.
24. WebMD. Onchocerciasis (river blindness). http://emedicine.medscape.com/ article/1109409-overview. Accessed June 28, 2009.
25. Murdoch ME, Hay RJ, Mackenzie CD, et al. A clinical classification and grading system of the cutaneous changes in onchocerciasis. Br J Dermatol 1993 : 129 : 260 269.
26. Rathinam SR, Cunningham ET, Jr. Infectious causes of uveitis in the developing world. Int Ophthalmol Clin 2000 : 40 : 137 152.
27. Weil GJ, Ramzy RM. Diagnostic tools for filariasis elimination programs. Trends Parasitol 2007 : 23 : 78 82.
28. Jr. JDTaWAP. Wuchereria bancrofti. In : Medical parasitology, 9th ed. St. Louis, MO : Elsevier Science : 2006 : 280.
29. Amaral F, Dreyer G, Figueredo-Silva J, et al. Live adult worms detected by ultrasonography in human Bancroftian filariasis. Am J Trop Med Hyg 1994 : 50 : 753 757.
30. Shenoy RK, John A, Hameed S, Suma TK, Kumaraswami V. Apparent failure of ultrasonography to detect adult worms of Brugia malayi. Ann Trop Med Parasitol 2000 : 94 : 77 82.
31. Shenoy RK, Suma TK, Kumaraswami V, et al. Lymphoscintigraphic evidence of lymph vessel dilation in the limbs of children with Brugia malayi infection. J Commun Dis 2008 : 40 : 91 100.
32. Molyneux DH. Filaria control and elimination: diagnostic, monitoring and surveillance needs. Trans R Soc Trop Med Hyg 2009 : 103 : 338 341.
33. Dickerson JW, Eberhard ML, Lammie PJ. A technique for microfilarial detection in preserved blood using nuclepore filters. J Parasitol 1990 : 76 : 829 833.
34. Tolan RW, Nissen MD, Walker JC. Bancroftian filariasis: differential diagnoses & workup. http://emedicine.medscape.com/article/996732-diagnosis. Accessed June 28, 2009.
35. Cheesbrough M, ed. District laboratory practice in tropical countries. Cambridge University Press : Cambridge, 1998.
36. Guzman GE, Awadzi K, Opoku N, Narayanan RB, Akuffo HO. Comparison between the skin snip test and simple dot blot assay as potential rapid assessment tools for Onchocerciasis in the postcontrol era in Ghana. Clin Diagn Lab Immunol 2002 : 9 : 1014 1020.
37. Thanomsub BW, Chonsiri K, Sarataphan N, Phantana S. Differential diagnosis of human lymphatic filariasis. Mol Cell Prob 2000 : 14 : 41 46.
38. Bockarie MJ, Taylor MJ, Gyapong JO. Current practices in the management of lymphatic filariasis. Expert Rev Anti-Infect Ther 2009 : 7 : 595 605.
39. Webber RH. Can anopheline-transmitted filariasis be eradicated? J Trop Med Hyg 1991 : 94 : 241 244.
40. Webber RH, Southgate BA. The maximum density of anopheline mosquitoes that can be permitted in the absence of continuing transmission of filariasis. Trans R Soc Trop Med Hyg 1981 : 75 : 499 506.
41. Webber RH. Eradication of Wuchereria bancrofti infection through vector control. Trans R Soc Trop Med Hyg 1979 : 73 : 722 724.
42. Webber RH. The natural decline of Wuchereria bancrofti infection in a vector control situation in the Solomon Islands. Trans R Soc Trop Med Hyg 1977 : 71 : 396 400.
43. Gbakima AA, Bockarie MJ, Sahr F, Palmer LT, Gooding E. Rapid assessment of the prevalence and distribution of lymphatic filariasis in Sierra Leone. Ann Trop Med Parasitol 2000 : 94 : 299 301.
44. Reuben R, Rajendran R, Sunish IP, et al. Annual single-dose diethylcarbamazine plus ivermectin for control of bancroftian filariasis: comparative efficacy with and without vector control. Ann Trop Med Parasitol 2001 : 95 : 361 378.
45. McGarry HF, Plant LD, Taylor MJ. Diethylcarbamazine activity against Brugia malayi microfilariae is dependent on inducible nitric-oxide synthase and the cyclooxygenase pathway. Filaria J 2005 : 4 : 4.
46. Maizels RM, Denham DA. Diethylcarbamazine (DEC): immunopharmacological interactions of an anti-filarial drug. Parasitology 1992 : 105 Suppl : S49 60.
47. Bockarie MJ, Alexander ND, Hyun P, et al. Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes. Lancet 1998 : 351 : 162 168.
48. Kazura J, Greenberg J, Perry R, Weil G, Day K, Alpers M. Comparison of single-dose diethylcarbamazine and ivermectin for treatment of bancroftian filariasis in Papua New Guinea. The American journal of tropical medicine and hygiene 1993 : 49 : 804 811.
49. Adinarayanan S, Critchley J, Das PK, Gelband H. Diethylcarbamazine (DEC)-medicated salt for community-based control of lymphatic filariasis. Cochrane database of systematic reviews (online) 2007 : CD003758.
50. Whitworth JA, Morgan D, Maude GH, McNicholas AM, Taylor DW. A field study of the effect of ivermectin on intestinal helminths in man. Trans R Soc Trop Med Hyg 1991 : 85 : 232 234.
51. Molyneux DH. Combating the "other diseases" of MDG 6: changing the paradigm to achieve equity and poverty reduction? Trans R Soc Trop Med Hyg 2008 : 102 : 509 519.
52. Bockarie MJ, Alexander ND, Kazura JW, Bockarie F, Griffin L, Alpers MP. Treatment with ivermectin reduces the high prevalence of scabies in a village in Papua New Guinea. Acta Tropica 2000 : 75 : 127 130.
53. Twum-Danso NA. Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future. Filaria J 2003 : 2 Suppl 1 : S7.
54. Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 1997 : 350 : 18 22.
55. Twum-Danso NA. Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases. Filaria J 2003 : 2 Suppl 1 : S3.
56. Dourmishev AL, Dourmishev LA, Schwartz RA. Ivermectin: pharmacology and application in dermatology. Int J Dermatol 2005 : 44 : 981 988.
57. Addiss D, Critchley J, Ejere H, Garner P, Gelband H, Gamble C. Albendazole for lymphatic filariasis. Cochrane database of systematic reviews (online) 2004 : CD003753.
58. Taylor MJ, Bandi C, Hoerauf A. Wolbachia bacterial endosymbionts of filarial nematodes. Adv Parasitol 2005 : 60 : 245 284.
59. Taylor MJ, Makunde WH, McGarry HF, Turner JD, Mand S, Hoerauf A. Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Lancet 2005 : 365 : 2116 2121.
60. Debrah AY, Mand S, Specht S, et al. Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis. PLoS pathogens 2006 : 2 : e92.
61. Debrah AY, Mand S, Toliat MR, et al. Plasma vascular endothelial growth Factor-A (VEGF-A) and VEGF-A gene polymorphism are associated with hydrocele development in lymphatic filariasis. Am J Trop Med Hyg 2007 : 77 : 601 608.
62. Cross HF, Haarbrink M, Egerton G, Yazdanbakhsh M, Taylor MJ. Severe reactions to filarial chemotherapy and release of Wolbachia endosymbionts into blood. Lancet 2001 : 358 : 1873 1875.
63. Cross HF HM, Egerton G, Yazdanbakhsh M, Taylor MJ. Severe reactions to filarial chemotherapy and release of Wolbachia endosymbionts into blood. Lancet 2001 : 358 : 1873 1875.
64. Hoerauf A. Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis. Curr Opin Infect Dis 2008 : 21 : 673 681.
65. Ottesen EA, Ismail MM, Horton J. The role of albendazole in programmes to eliminate lymphatic filariasis. Parasitol Today (Personal ed) 1999 : 15 : 382 386.
66. Ramzy RM, El Setouhy M, Helmy H, et al. Effect of yearly mass drug administration with diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: a comprehensive assessment. Lancet 2006 : 367 : 992 999.
67. Seketeli A, Adeoye G, Eyamba A, et al. The achievements and challenges of the African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol 2002 : 96 Suppl 1 : S15 28.
68. Homeida M, Braide E, Elhassan E, et al. APOC's strategy of community-directed treatment with ivermectin (CDTI) and its potential for providing additional health services to the poorest populations. African Programme for Onchocerciasis Control. Ann Trop Med Parasitol 2002 : 96 Suppl 1 : S93 104.
69. Amazigo UV, Obono M, Dadzie KY, et al. Monitoring community-directed treatment programmes for sustainability: lessons from the African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol 2002 : 96 Suppl 1 : S75 92.
70. Amazigo UV, Brieger WR, Katabarwa M, et al. The challenges of community-directed treatment with ivermectin (CDTI) within the African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol 2002 : 96 Suppl 1 : S41 58.
71. Ramaiah KD, Das PK, Vanamail P, Pani SP. The impact of six rounds of single-dose mass administration of diethylcarbamazine or ivermectin on the transmission of Wuchereria bancrofti by Culex quinquefasciatus and its implications for lymphatic filariasis elimination programmes. Trop Med Int Health 2003 : 8 : 1082 1092.
72. Partono F, Maizels RM, Purnomo. Towards a filariasis-free community: evaluation of filariasis control over an eleven year period in Flores, Indonesia. Trans R Soc Trop Med Hyg 1989 : 83 : 821 826.
73. Meyrowitsch DW, Simonsen PE, Magesa SM. Long-term effect of three different strategies for mass diethylcarbamazine administration in bancroftian filariasis: follow-up at 10 years after treatment. Trans R Soc Trop Med Hyg 2004 : 98 : 627 634.
74. Meyrowitsch DW, Simonsen PE. Long-term effect of mass diethylcarbamazine chemotherapy on bancroftian filariasis, results at four years after start of treatment. Trans R Soc Trop Med Hyg 1998 : 92 : 98 103.
75. Dreyer GAD, Dreyer P, Noroes J. Basic lymphoedema management. Hollis, NH : Hollis Publishing Company, 2002.
76. Specht S, Wanji S. New insights into the biology of filarial infections. J Helminthol 2009 : 83 : 199 202.
77. Vedi S, Dangi A, Hajela K, Misra-Bhattacharya S. Vaccination with 73 kDa recombinant heavy chain myosin generates high level of protection against Brugia malayi challenge in jird and mastomys models. Vaccine 2008 : 26 : 5997 6005.
78. Vanam U, Pandey V, Prabhu PR, Dakshinamurthy G, Reddy MV, Kaliraj P. Evaluation of immunoprophylactic efficacy of Brugia malayi transglutaminase (BmTGA) in single and multiple antigen vaccination with BmALT-2 and BmTPX for human lymphatic filariasis. The Am J Trop Med Hyg 2009 : 80 : 319 324.
79. Anosike JC, Dozie IN, Onwuliri CO, Nwoke BE, Onwuliri VA. Prevalence of Mansonella perstans infections among the nomadic Fulanis of northern Nigeria. Ann Agric Environ Med 2005 : 12 : 35 38.